HRT and Blood Clot (VTE) Risk

HRT and blood clot risk

This is not medical advice — it is general information based on what you searched for that may help.

General information based on published sources and the symptoms you searched for. This isn't medical or legal advice, a diagnosis or a treatment plan. Please consult a doctor about your own symptoms. If your symptoms are severe or sudden, seek urgent care.

This page may not apply to you if:

People with a personal or strong family history of VTE, or a known hereditary thrombophilia, need specialist assessment before starting HRT

Of all the safety questions around hormone therapy, blood clot (venous thromboembolism, or VTE) and stroke risk are where the route you take it — not just the decision to take it — makes the biggest difference. NICE guideline NG23 is specific about this.

Blood clots (VTE): patch and gel are not the same as a pill

Transdermal HRT (patch or gel): VTE risk is not increased.
Oral HRT (pills): VTE risk is increased, and is greater than with transdermal HRT.

This is one reason NICE specifically recommends considering transdermal HRT instead of oral HRT for people already at higher VTE risk, including those with a BMI over 30. See our patch vs. pill comparison for more on how the two routes differ.

If you have a strong family history of blood clots, or a known hereditary thrombophilia, NICE recommends being referred to a haematologist for assessment before considering HRT at all — not after a clot has already happened.

Stroke: route and dose both matter

Baseline stroke risk in women under 60 is very low to begin with.
Combined HRT with transdermal estrogen: stroke risk is unlikely to increase.
Combined HRT with oral estrogen: stroke risk increases, and rises further with higher estrogen dose, longer duration of use (for example, more than 5 years), and older age at first starting HRT. NICE also notes this risk differs between ethnic groups and may be greater in Black people.
Estrogen-only HRT, oral: stroke risk increases, rising with dose and with age at starting.
Estrogen-only HRT, transdermal: stroke risk is unlikely to increase.

See our heart health after menopause guide for the broader cardiovascular picture, including why HRT isn't used to prevent heart disease even though these specific risks are route-dependent.

What this means in practice

For most of these risks, the pattern is consistent: transdermal (through-the-skin) estrogen carries a more favorable safety profile for clotting and stroke than oral estrogen, which is why it's often the preferred starting point for people with any additional risk factors. This doesn't automatically rule oral HRT out for everyone — it's a conversation about your personal risk factors, not a blanket rule.

Prepare for your appointment

If you're weighing HRT against non-hormonal options because of these risks, our Does It Work? evidence directory grades the alternatives honestly. Use our treatment conversation builder to bring these questions to your appointment:

Given my personal and family history of blood clots or stroke, would a transdermal (patch or gel) option be safer for me than a pill?
Do I need a haematology referral before starting HRT because of my VTE risk factors?

Where are you right now?

Still tracking

Not sure if your symptoms fit? Start tracking your daily patterns.

Log and spot your patterns with the symptom checklist →

Ready to talk to a doctor

Have an upcoming appointment? Bring structured questions and your history.

Prepare your 10-minute doctor appointment questions →

Already on treatment

Evaluating your response or wondering what to adjust next?

Explore evidence-graded treatment and lifestyle options →

Questions people ask

Does HRT increase blood clot risk?

It depends heavily on the route. NICE guidance states that oral HRT (pills) increases VTE (blood clot) risk, and that risk is higher than with transdermal HRT (patches or gel), which NICE states does not increase VTE risk.

Is a patch safer than a pill for blood clot and stroke risk?

Based on NICE guidance, yes, specifically for these two risks: transdermal (patch or gel) estrogen is not associated with increased VTE risk, and is unlikely to increase stroke risk, while oral estrogen increases both, with stroke risk rising further with higher doses, longer use, and older age at starting.